over 2 years ago However, management was apprehensive about soft procedure volume and declining revenues in Japan, which was down in April but have been stable till May’s earnings call. Net sales for dental, spine and craniomaxillofacial and thoracic products were down nearly 38 percent at $182.5 million.6. 01656 655221
In the second quarter, Zimmer used $52.8 million of net cash in operating activities. Zimmer Biomet (NYSE:ZBH): Q2 Non-GAAP EPS of $0.05 beats by $0.74; GAAP EPS of -$1.00 beats by $0.79.Revenue of $1.23B (-38.2% Y/Y) beats … Zimmer Biomet Holdings, Inc. (ZBH - Free Report) posted second-quarter 2020 adjusted earnings per share (EPS) of 5 cents in contrast to the Zacks Consensus Estimate of a loss of 72 cents per share.
Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Zimmer was mixed. Free cash flow is computed by deducting additions to instruments and other property, plant and equipment from net cash (used in) provided by operating activities.Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release.
This may take up to 72 hours, if you do not receive this verification email, please contact us at This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Zacks Ranks stocks can, and often do, change throughout the month. The global decrease for hips was 31.1 percent, leaving Zimmer with $329.7 million in overall net sales for that category in the second quarter.5.
Zimmer Biomet, during its first quarter earnings call in May, confirmed the month of April to be the most challenging one although the company expected business to recover after April.The company is optimistic about improvement in procedure volumes in China since the latter half of March.
Revenue for the quarter came in … By renegotiating terms of its $1.5 billion revolver, Zimmer secured an additional $1 billion credit facility with no outstanding borrowings.8. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. So, the shares are expected to perform in line with the market in the near future. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. The company paid $49.6 million in dividends and declared a dividend of $0.24 per share in the second quarter, when it also refinanced $1.5 billion in debt due April 1. There are no videos available for your current audience. Zimmer Biomet is proud to announce that President and CEO Bryan Hanson has been named a 2020 Top 50 Healthcare Technology CEO by the Healthcare Technology Report. Show 36 results for Healthcare Professional content Zimmer ended the quarter with $713.4 million in cash and cash equivalents on its balance sheet.7. Also, the consensus estimate for loss per share is pegged at 75 cents against earnings of $1.93 in the year-ago quarter.Our proven model predicts an earnings beat for Zimmer Biomet this time around. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price quickly amid the global health crisis. Alongside some of the world's top healthcare professionals, we help deliver new possibilities to patients. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations. A recent pick, Maxar, skyrocketed For 32 years, our Strong Buy list has averaged returns more than twice the market. Powered by Madgex Job Board Software The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 25% of the 250 plus Zacks industries. COVID-19 caused a worldwide decline in elective procedure volumes, hurting Zimmer Biomet's performance in the three months ended June 30 and leading the company to pull its full-year guidance. Zimmer Biomet is a publicly traded medical device company. Zimmer Biomet Holdings (NYSE: ZBH) reported Q2 EPS of $0.05, $0.78 better than the analyst estimate of ($0.73).